For individuals · United States
Peptide Evidence Watch translates peptide research and regulatory developments into plain English—without protocols, sourcing, product promotion, or pretending early science is settled.
Get meaningful updatesEvidence signal · Insufficient evidence for FDA-reviewed use
The staff proposal, reported advisory vote, human evidence, active trial, and remaining final-action gap are mapped in the full review.
Read the full evidence review →Evidence signal · No human data identified by FDA
Research on thymosin beta-4 does not automatically establish claims for products marketed as TB-500.
Evidence signal · No human administration data identified by FDA
Mechanistic interest does not establish a clinical benefit or safety in people.
Evidence signal · Mixed evidence by application
Topical research cannot automatically support claims about injectable use.
These are research and policy summaries, not safety determinations or treatment recommendations. FDA proposals and advisory discussions are not final agency action. Read the July 2026 FDA meeting record.
For health topics, the useful answer often includes what is unknown. We show the evidence lane, the regulatory lane, and where online claims outrun either one.
Is this product FDA-approved, compounded for an individual patient, or neither?
What human clinical evidence supports the specific use being discussed?
Which licensed prescriber and pharmacy would be responsible for care and dispensing?
What uncertainties, adverse effects, and alternative options should I understand?
Choose what you care about. Every meaningful update links to the original source, labels the evidence type, and explains what the development does—and does not—mean.